Core Viewpoint - Legend Biotech has reportedly canceled its sales and marketing team in China, raising concerns about the market presence of its CAR-T drug, ciltacabtagene autoleucel (also known as cilta-cel) [2] Group 1: Product Overview - Ciltacabtagene autoleucel injection has achieved overall sales of $963 million in 2024, making it one of the best-selling CAR-T drugs in China [3] - The drug was first approved for the U.S. market in February 2022 for treating adult patients with relapsed or refractory multiple myeloma and received approval in China in August 2024 [2][3] - The initial pricing for ciltacabtagene autoleucel in the U.S. was $465,000, significantly higher than other CAR-T drugs in China, which are typically priced around one million yuan or more [3] Group 2: Market Dynamics - Despite its approval in China, ciltacabtagene autoleucel has not been sold in the Chinese market, with all sales currently coming from the U.S. and European markets [2][3] - The promotion of CAR-T drugs in China is hindered by payment issues, as no CAR-T drugs have been included in the Chinese medical insurance catalog to date [3] Group 3: Financial Performance - As of the first quarter of 2025, ciltacabtagene autoleucel has benefited over 6,000 patients in clinical and commercial treatments, but the company has not yet turned a profit, reporting a net loss of $100.9 million [3] - The company aims to achieve profitability by 2026 according to its previous plans [4]